Document is current
Any future updates will be listed below
-
Authors
van Velzen, Merel J. M. http://orcid.org/0000-0002-0102-1466
Creemers, Aafke
van den Ende, Tom
Schokker, Sandor
Krausz, Sarah
Reinten, Roy J.
Dijk, Frederike
van Noesel, Carel J. M.
Halfwerk, Hans
Meijer, Sybren L.
Mearadji, Banafsche
Derks, Sarah
Bijlsma, Maarten F.
van Laarhoven, Hanneke W. M.
-
Funding
Funding for this research was provided by:
De Jonge Akademie (UPS/RB/745)
Nijbakker Morra Stichting
- License Information
-
More Information
Article History
Received: 4 March 2022
Accepted: 25 May 2022
First Online: 28 June 2022
Declarations
:
: MFB received research funding from Celgene. Prof. dr. Hanneke W. M. van Laarhoven has served as a consultant for Celgene, Lilly, Nordic, and Philips, and has received unrestricted research funding from Bayer, Celgene, Lilly, Merck, Serono, MSD, Nordic, Philips and Roche. None of these parties were involved in the current study.
: The medical ethical committee of the Amsterdam UMC, location AMC approved the collection of patient material in the BiOES prospective biobank of the Amsterdam UMC (AMC 2013_241) in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: All patients provided written informed consent to participate in the BiOES prospective biobank of the Amsterdam AUMC.
